Midatech Pharma plc

Midatech Pharma plc

MTP

MTPMidatech Pharma plc US flag

NASDAQ Capital Market

0.29

USD

-0.06

- -

1.98MMarket Cap

Midatech Pharma plc

MTP

(NASDAQ Capital Market)

Recent

price

0.29

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: MacroGenics, Inc. (MGNX)
MBX Biosciences, Inc. Common Stock (MBX)
Galera Therapeutics, Inc. (GRTX)
ProMIS Neurosciences, Inc. (PMN)
CG Oncology Inc. (CGON)
Gain Therapeutics, Inc. (GANX)
Business: Midatech Pharma plc, now operating as Biodexa Pharmaceuticals Plc (NASDAQ: BDRX; formerly ticker MTP), is a clinical-stage biopharmaceutical company headquartered in Cardiff, United Kingdom, and founded in 2000 that develops innovative therapies and drug delivery technologies targeting diseases with high unmet medical needs, including familial adenomatous polyposis (FAP), type 1 diabetes, and rare/orphan brain cancers such as diffuse midline glioma, glioblastoma, and medulloblastoma; its core pipeline includes eRapa, a proprietary oral nanoparticle formulation of rapamycin (sirolimus), an mTOR inhibitor advancing toward a phase 3 registration trial (Serenta) in FAP with orphan drug designation in the US and recent $25.5 million CPRIT grant funding secured for the program through NDA submission; Tolimidone, an oral lyn kinase activator in phase 2 development for type 1 diabetes demonstrating glycemic control via insulin sensitization in preclinical models; and MTX110, a MidaSolve-formulated panobinostat in phase 1/2 for recurrent glioblastoma and other aggressive brain tumors, showing improved survival in early data; the company leverages proprietary platforms including Q-Sphera for sustained-release microspheres, MidaSolve oligosaccharide nanotechnology for tumor-localized liquid delivery, and MidaCore gold nanoparticles for targeted chemotherapy or immunotherapy; recent developments encompass a March 2023 name change and rebranding from Midatech Pharma to Biodexa Pharmaceuticals, strategic acquisitions or licenses of eRapa and Tolimidone in 2023-2024 with low upfront costs paid in shares, a $5.0 million registered direct offering closed in July 2024 to fund eRapa phase 3 matching payments and working capital, $7 million in warrant exercise proceeds in May 2024, positive phase 2 eRapa data in FAP showing 29% median polyp burden reduction and 89% non-progression rate, and FDA interactions advancing phase 3 recruitment planned for early 2025 alongside phase 2 initiation for Tolimidone and interim NMIBC data.

Company News